Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

131.83  -0.19 (-0.14%)

After market: 131.83 0 (0%)

Fundamental Rating

7

NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. NBIX is not overvalued while it is showing excellent growth. This is an interesting combination. With these ratings, NBIX could be worth investigating further for growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year NBIX was profitable.
In the past year NBIX had a positive cash flow from operations.
Each year in the past 5 years NBIX has been profitable.
Each year in the past 5 years NBIX had a positive operating cash flow.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

NBIX has a better Return On Assets (8.29%) than 94.24% of its industry peers.
The Return On Equity of NBIX (12.06%) is better than 94.42% of its industry peers.
NBIX's Return On Invested Capital of 11.52% is amongst the best of the industry. NBIX outperforms 95.86% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 14.97%.
The last Return On Invested Capital (11.52%) for NBIX is above the 3 year average (11.40%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.29%
ROE 12.06%
ROIC 11.52%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

NBIX has a better Profit Margin (12.68%) than 93.53% of its industry peers.
NBIX's Profit Margin has improved in the last couple of years.
NBIX's Operating Margin of 20.78% is amongst the best of the industry. NBIX outperforms 95.68% of its industry peers.
NBIX's Operating Margin has declined in the last couple of years.
NBIX has a Gross Margin of 98.52%. This is amongst the best in the industry. NBIX outperforms 98.20% of its industry peers.
NBIX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 20.78%
PM (TTM) 12.68%
GM 98.52%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NBIX is still creating some value.
NBIX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

NBIX has an Altman-Z score of 8.27. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 8.27, NBIX belongs to the best of the industry, outperforming 83.99% of the companies in the same industry.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.27
ROIC/WACC1.18
WACC9.74%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

NBIX has a Current Ratio of 3.13. This indicates that NBIX is financially healthy and has no problem in meeting its short term obligations.
NBIX has a worse Current ratio (3.13) than 63.67% of its industry peers.
A Quick Ratio of 3.02 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a worse Quick ratio (3.02) than 62.95% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.02
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

NBIX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -18.73%.
NBIX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 58.39% yearly.
NBIX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.73%.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)-18.73%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-80.95%
Revenue 1Y (TTM)21.73%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%11.12%

3.2 Future

NBIX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.48% yearly.
The Revenue is expected to grow by 11.62% on average over the next years. This is quite good.
EPS Next Y21.15%
EPS Next 2Y37.1%
EPS Next 3Y36.19%
EPS Next 5Y35.48%
Revenue Next Year14.18%
Revenue Next 2Y14.7%
Revenue Next 3Y13.91%
Revenue Next 5Y11.62%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 44.69, the valuation of NBIX can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.81% of the companies listed in the same industry.
NBIX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.54.
NBIX is valuated rather expensively with a Price/Forward Earnings ratio of 21.32.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.27% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, NBIX is valued a bit cheaper.
Industry RankSector Rank
PE 44.69
Fwd PE 21.32
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

NBIX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NBIX is cheaper than 94.60% of the companies in the same industry.
93.70% of the companies in the same industry are more expensive than NBIX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 26.51
EV/EBITDA 21.46
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NBIX does not grow enough to justify the current Price/Earnings ratio.
NBIX has an outstanding profitability rating, which may justify a higher PE ratio.
NBIX's earnings are expected to grow with 36.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.11
PEG (5Y)0.77
EPS Next 2Y37.1%
EPS Next 3Y36.19%

More info and screens

0

5. Dividend

5.1 Amount

NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (7/21/2025, 4:30:01 PM)

After market: 131.83 0 (0%)

131.83

-0.19 (-0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners97.31%
Inst Owner Change0.41%
Ins Owners1.02%
Ins Owner Change2.5%
Market Cap13.05B
Analysts83.75
Price Target163.5 (24.02%)
Short Float %3.65%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-61.4%
Min EPS beat(2)-85.62%
Max EPS beat(2)-37.18%
EPS beat(4)0
Avg EPS beat(4)-45.39%
Min EPS beat(4)-85.62%
Max EPS beat(4)-17.35%
EPS beat(8)2
Avg EPS beat(8)-26.8%
EPS beat(12)2
Avg EPS beat(12)-90.12%
EPS beat(16)3
Avg EPS beat(16)-79.13%
Revenue beat(2)0
Avg Revenue beat(2)-1.15%
Min Revenue beat(2)-2.16%
Max Revenue beat(2)-0.14%
Revenue beat(4)2
Avg Revenue beat(4)1.31%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)5.99%
Revenue beat(8)3
Avg Revenue beat(8)0.56%
Revenue beat(12)6
Avg Revenue beat(12)1.13%
Revenue beat(16)8
Avg Revenue beat(16)0.68%
PT rev (1m)1.76%
PT rev (3m)-1.77%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)-0.41%
EPS NY rev (1m)-0.51%
EPS NY rev (3m)-4.88%
Revenue NQ rev (1m)-0.16%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.66%
Valuation
Industry RankSector Rank
PE 44.69
Fwd PE 21.32
P/S 5.41
P/FCF 26.51
P/OCF 24.62
P/B 5.15
P/tB 5.22
EV/EBITDA 21.46
EPS(TTM)2.95
EY2.24%
EPS(NY)6.18
Fwd EY4.69%
FCF(TTM)4.97
FCFY3.77%
OCF(TTM)5.35
OCFY4.06%
SpS24.38
BVpS25.62
TBVpS25.25
PEG (NY)2.11
PEG (5Y)0.77
Profitability
Industry RankSector Rank
ROA 8.29%
ROE 12.06%
ROCE 15.84%
ROIC 11.52%
ROICexc 16.41%
ROICexgc 16.69%
OM 20.78%
PM (TTM) 12.68%
GM 98.52%
FCFM 20.4%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score8
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 132.28%
Cap/Sales 1.56%
Interest Coverage 250
Cash Conversion 100%
Profit Quality 160.96%
Current Ratio 3.13
Quick Ratio 3.02
Altman-Z 8.27
F-Score8
WACC9.74%
ROIC/WACC1.18
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)-18.73%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-80.95%
EPS Next Y21.15%
EPS Next 2Y37.1%
EPS Next 3Y36.19%
EPS Next 5Y35.48%
Revenue 1Y (TTM)21.73%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%11.12%
Revenue Next Year14.18%
Revenue Next 2Y14.7%
Revenue Next 3Y13.91%
Revenue Next 5Y11.62%
EBIT growth 1Y6.59%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year-5.36%
EBIT Next 3Y24.51%
EBIT Next 5Y20.43%
FCF growth 1Y107.42%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y108.05%
OCF growth 3Y32.41%
OCF growth 5Y31.38%